CL2017001859A1 - Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol - Google Patents
Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterolInfo
- Publication number
- CL2017001859A1 CL2017001859A1 CL2017001859A CL2017001859A CL2017001859A1 CL 2017001859 A1 CL2017001859 A1 CL 2017001859A1 CL 2017001859 A CL2017001859 A CL 2017001859A CL 2017001859 A CL2017001859 A CL 2017001859A CL 2017001859 A1 CL2017001859 A1 CL 2017001859A1
- Authority
- CL
- Chile
- Prior art keywords
- fluticasone propionate
- dry powder
- dose
- patient
- salmeterol
- Prior art date
Links
- 229960000289 fluticasone propionate Drugs 0.000 title abstract 5
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title abstract 5
- GIIZNNXWQWCKIB-UHFFFAOYSA-N Serevent Chemical compound C1=C(O)C(CO)=CC(C(O)CNCCCCCCOCCCCC=2C=CC=CC=2)=C1 GIIZNNXWQWCKIB-UHFFFAOYSA-N 0.000 title abstract 3
- 229940112141 dry powder inhaler Drugs 0.000 title abstract 2
- 229960004017 salmeterol Drugs 0.000 title 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 2
- 239000008101 lactose Substances 0.000 abstract 2
- 229960005018 salmeterol xinafoate Drugs 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940126601 medicinal product Drugs 0.000 abstract 1
- 239000000843 powder Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0005—Details of inhalators; Constructional features thereof with means for agitating the medicament
- A61M15/0006—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means
- A61M15/0008—Details of inhalators; Constructional features thereof with means for agitating the medicament using rotating means rotating by airflow
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M15/00—Inhalators
- A61M15/0001—Details of inhalators; Constructional features thereof
- A61M15/0021—Mouthpieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M16/00—Devices for influencing the respiratory system of patients by gas treatment, e.g. ventilators; Tracheal tubes
- A61M16/10—Preparation of respiratory gases or vapours
- A61M16/14—Preparation of respiratory gases or vapours by mixing different fluids, one of them being in a liquid phase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2202/00—Special media to be introduced, removed or treated
- A61M2202/06—Solids
- A61M2202/064—Powder
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
<p>ESTA INVENCIÓN PROPORCIONA UN INHALADOR DE POLVO SECO QUE COMPRENDE: UN MEDICAMENTO EN POLVO SECO QUE COMPRENDE PROPIONATO DE FLUTICASONA, XINAFOATO DE SALMETEROL Y UN PORTADOR DE LACTOSA; EN DONDE, LA DOSIS SUMINISTRADA DE PROPIONATO DE FLUTICASONA POR DESCARGA ES INFERIOR A 100 G; Y EN DONDE LA DOSIS PROPORCIONA UN FEV1 EN UN PACIENTE, AJUSTADO AL VALOR BASAL, SUPERIOR A 150 ML DENTRO DE 30 MINUTOS DE RECIBIDA LA DOSIS. UN MÉTODO DE TRATAMIENTO DE UN PACIENTE QUE INCLUYE LA ADMINISTRACIÓN A UN PACIENTE UN MEDICAMENTO EN POLVO SECO QUE TIENE PROPIONATO DE FLUTICASONA, XINAFOATO DE SALMETEROL Y UN PORTADOR DE LACTOSA; EN DONDE, LA DOSIS ENTREGADA DE PROPIONATO DE FLUTICASONA POR DESCARGA ES INFERIOR A 100 µG; Y EN DONDE LA DOSIS PROPORCIONA UN FEV1 EN UN PACIENTE, AJUSTADO AL VALOR BASAL, SUPERIOR A 150 ML DENTRO DE 30 MINUTOS DE RECIBIDA LA DOSIS.</p>
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562105479P | 2015-01-20 | 2015-01-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2017001859A1 true CL2017001859A1 (es) | 2018-04-06 |
Family
ID=55443303
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2017001859A CL2017001859A1 (es) | 2015-01-20 | 2017-07-18 | Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol |
Country Status (19)
Country | Link |
---|---|
US (2) | US9415008B2 (es) |
EP (1) | EP3247331A1 (es) |
JP (1) | JP2018503687A (es) |
KR (1) | KR20170103975A (es) |
CN (1) | CN107530357A (es) |
AR (1) | AR104771A1 (es) |
AU (2) | AU2016209363B2 (es) |
BR (1) | BR112017015353A2 (es) |
CA (1) | CA2974125A1 (es) |
CL (1) | CL2017001859A1 (es) |
CO (1) | CO2017008395A2 (es) |
EA (1) | EA201791632A1 (es) |
HK (1) | HK1245125A1 (es) |
IL (1) | IL253499A0 (es) |
MA (1) | MA41378A (es) |
MX (2) | MX2017009122A (es) |
PE (1) | PE20171258A1 (es) |
TW (1) | TW201628607A (es) |
WO (1) | WO2016118589A1 (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2863198T3 (es) * | 2013-10-07 | 2021-10-08 | Teva Branded Pharmaceutical Products R&D Inc | Inhalador de polvo seco |
MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
KR102539907B1 (ko) * | 2016-11-18 | 2023-06-05 | 노턴 (워터포드) 리미티드 | 전자 장치를 구비한 약물 전달 기구 |
CN110201280B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药装置的吸嘴和吸入给药装置 |
CN110201278B (zh) * | 2018-02-28 | 2021-07-30 | 张江 | 用于吸入给药的药盒和吸入给药组合结构 |
CN110201281B (zh) * | 2018-02-28 | 2021-08-06 | 张江 | 吸入给药装置和吸入给药组合结构 |
CN110064110A (zh) * | 2019-05-29 | 2019-07-30 | 上海理工大学 | 一种容积旋钮式干粉储存吸入装置 |
GB2585206B (en) * | 2019-07-01 | 2021-08-11 | Merxin Ltd | Portable inhaler |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5270305A (en) * | 1989-09-08 | 1993-12-14 | Glaxo Group Limited | Medicaments |
US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
GB0008660D0 (en) * | 2000-04-07 | 2000-05-31 | Arakis Ltd | The treatment of respiratory diseases |
PE20020067A1 (es) * | 2000-06-23 | 2002-02-05 | Norton Healthcare Ltd | Desaglomerador para inhalador de polvo seco accionado por la respiracion |
TWI224514B (en) | 2000-06-23 | 2004-12-01 | Norton Healthcare Ltd | Dose metering system for medicament inhaler |
PE20020387A1 (es) * | 2000-08-31 | 2002-06-24 | Glaxo Group Ltd | Uso de una combinacion de salmeterol y fluticasona |
PT1337240E (pt) * | 2000-11-30 | 2011-11-02 | Vectura Ltd | Método de fabrico de partículas para utilização numa composição farmacêutica |
GB0124523D0 (en) * | 2001-10-12 | 2001-12-05 | Glaxo Group Ltd | Pharmaceutical combination |
AU2003279070A1 (en) | 2002-09-30 | 2004-04-23 | Acusphere Inc | Sustained release porous microparticles for inhalation |
US9114081B2 (en) * | 2007-05-07 | 2015-08-25 | Insmed Incorporated | Methods of treating pulmonary disorders with liposomal amikacin formulations |
US20110135737A1 (en) * | 2009-05-29 | 2011-06-09 | Pearl Therapeutics, Inc. | Compositions for respiratory delivery of active agents and associated methods and systems |
US20110229437A1 (en) * | 2009-09-17 | 2011-09-22 | Mutual Pharmaceutical Company, Inc. | Method of Treating Asthma with Antiviral Agents |
GB0919465D0 (en) * | 2009-11-06 | 2009-12-23 | Norton Healthcare Ltd | Airflow adaptor for a breath-actuated dry powder inhaler |
EA201690641A1 (ru) * | 2010-05-18 | 2016-08-31 | Ивакс Фармасьютикалз Аэрлэнд | Инкрементальный счетчик доз для ингалятора отмеренных доз |
EP2571486A4 (en) * | 2010-05-20 | 2013-12-04 | Sun Pharma Advanced Res Co Ltd | DRY POWDER INHALATION COMPOSITION |
KR20130140358A (ko) * | 2012-06-14 | 2013-12-24 | 한미약품 주식회사 | 살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법 |
WO2014177520A1 (en) * | 2013-04-29 | 2014-11-06 | Sanofi Sa | Inhalable pharmaceutical compositions and the inhaler devices containing them |
ES2863198T3 (es) * | 2013-10-07 | 2021-10-08 | Teva Branded Pharmaceutical Products R&D Inc | Inhalador de polvo seco |
PE20170690A1 (es) * | 2014-10-16 | 2017-05-25 | Teva Branded Pharmaceutical Products Randd Inc | Formulacion de polvo seco |
MA41378A (fr) * | 2015-01-20 | 2017-11-28 | Teva Branded Pharmaceutical Prod R & D Inc | Inhalateur de poudre sèche comprenant du propionate de fluticasone et du xinafoate de salmétérol |
-
2016
- 2016-01-19 MA MA041378A patent/MA41378A/fr unknown
- 2016-01-20 EA EA201791632A patent/EA201791632A1/ru unknown
- 2016-01-20 WO PCT/US2016/014072 patent/WO2016118589A1/en active Application Filing
- 2016-01-20 TW TW105101637A patent/TW201628607A/zh unknown
- 2016-01-20 PE PE2017001234A patent/PE20171258A1/es unknown
- 2016-01-20 EP EP16706919.4A patent/EP3247331A1/en not_active Withdrawn
- 2016-01-20 CA CA2974125A patent/CA2974125A1/en not_active Abandoned
- 2016-01-20 BR BR112017015353A patent/BR112017015353A2/pt not_active Application Discontinuation
- 2016-01-20 MX MX2017009122A patent/MX2017009122A/es unknown
- 2016-01-20 CN CN201680011413.7A patent/CN107530357A/zh active Pending
- 2016-01-20 US US15/001,853 patent/US9415008B2/en active Active
- 2016-01-20 AR ARP160100136A patent/AR104771A1/es active IP Right Grant
- 2016-01-20 KR KR1020177023075A patent/KR20170103975A/ko not_active Application Discontinuation
- 2016-01-20 AU AU2016209363A patent/AU2016209363B2/en active Active
- 2016-01-20 JP JP2017556791A patent/JP2018503687A/ja active Pending
- 2016-01-20 US US15/544,900 patent/US20180015035A1/en not_active Abandoned
-
2017
- 2017-07-12 MX MX2021006751A patent/MX2021006751A/es unknown
- 2017-07-16 IL IL253499A patent/IL253499A0/en unknown
- 2017-07-18 CL CL2017001859A patent/CL2017001859A1/es unknown
- 2017-08-17 CO CONC2017/0008395A patent/CO2017008395A2/es unknown
-
2018
- 2018-04-11 HK HK18104726.3A patent/HK1245125A1/zh unknown
-
2021
- 2021-05-04 AU AU2021202784A patent/AU2021202784A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
IL253499A0 (en) | 2017-09-28 |
PE20171258A1 (es) | 2017-08-28 |
EP3247331A1 (en) | 2017-11-29 |
JP2018503687A (ja) | 2018-02-08 |
MX2021006751A (es) | 2021-07-15 |
US9415008B2 (en) | 2016-08-16 |
AU2021202784A1 (en) | 2021-05-27 |
WO2016118589A1 (en) | 2016-07-28 |
US20180015035A1 (en) | 2018-01-18 |
EA201791632A1 (ru) | 2017-12-29 |
CO2017008395A2 (es) | 2018-01-05 |
HK1245125A1 (zh) | 2018-08-24 |
AU2016209363B2 (en) | 2021-02-04 |
CN107530357A (zh) | 2018-01-02 |
US20160206559A1 (en) | 2016-07-21 |
MA41378A (fr) | 2017-11-28 |
CA2974125A1 (en) | 2016-07-28 |
TW201628607A (zh) | 2016-08-16 |
MX2017009122A (es) | 2017-10-12 |
BR112017015353A2 (pt) | 2018-01-16 |
AU2016209363A1 (en) | 2017-08-24 |
AR104771A1 (es) | 2017-08-16 |
KR20170103975A (ko) | 2017-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2017001859A1 (es) | Inhalador de polvo seco que comprende propionato de fluticasona y xinafosfato de salmeterol | |
MX2016004316A (es) | Inhalador de polvo seco. | |
MX2019011117A (es) | Anticuerpo b7-h3, fragmento de union a antigeno de los mismos y uso medico de los mismos. | |
PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
MY191380A (en) | Stabilized fixed dose drug composition having mometasone and olopatadine | |
MX2022003072A (es) | Uso de pridopidina para el tratamiento de la disminucion funcional. | |
MA40539A (fr) | Procédés de formulation de compositions de conjugués anticorps-médicaments | |
BR112019005168A2 (pt) | composição farmacêutica, recipiente vedado, inalador de dose medida, e, métodos para tratar um paciente que sofre ou susceptível de sofrer de um distúrbio respiratório, para melhoria da estabilidade de uma composição farmacêutica e do desempenho de aerossolização de uma composição farmacêutica e para reduzir o potencial de aquecimento global de uma composição farmacêutica | |
MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation | |
MX2017003561A (es) | Composiciones y metodos para revestimientos cannabinoides para su uso en la administracion de farmacos. | |
MX2017013636A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde diferentes particulas. | |
NZ731431A (en) | Rapamycin powders for pulmonary delivery | |
MX2017013950A (es) | Polvos de zolmitriptán para suministro pulmonar. | |
MX2015009546A (es) | Dosificacion aumentada de efavirenz para el tratamiento de cancer. | |
MX2019004736A (es) | Mini-tabletas de melatonina y metodos de fabricacion de las mismas. | |
MX2017013633A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas. | |
MX2018005876A (es) | Regimen de dosificacion de plasminogeno para la cicatrizacion de heridas. | |
PH12018500889A1 (en) | Pharmaceutical preparation for delivery of porous material to large intestine or lower part of small intestine | |
MX2017013634A (es) | Combinacion de dosis fija resistente a la manipulacion que proporciona una liberacion rapida de dos farmacos desde particulas y un polvo. | |
MX2016010087A (es) | Filtros para equipos de infusion. | |
AR102903A1 (es) | Inhalador de polvo seco | |
TH173838A (th) | เครื่องพ่นละอองยาผงแห้ง | |
BR112016026460A8 (pt) | micropartículas de múltiplos componentes, seu processo de preparação, formulações farmacêuticas e inaladores | |
MX2017016423A (es) | Polvos de zolmitriptán para sumunistro pulmonar. | |
UA105586U (uk) | Спосіб лікування печінкової енцефалопатії |